Bio & Pharmaceuticals

Print
MA: EVIO Labs Massachusetts Announces Relocation to Framingham

20 Sep, 2018


EVIO Inc. ("EVIO" or the "Company"), (OTCQB: EVIO), a leading provider of cannabis testing and scientific research for the regulated cannabis industry in North America, announced that its Massachusetts lab has engaged in a Community Host agreement with the City of Framingham to proceed with licensing as an independent testing laboratory under the Commission's recently adopted adult use regulations.  This is on the heels of the announcement that the lab had received ISO 17025 accreditation and is awaiting licensing approval from the Cannabis Control Commission.

The lab will move to a 5,000-square-foot facility that is centrally located to serve marijuana establishments statewide. Massachusetts law requires that all recreational marijuana products have been tested by a Commission-licensed independent laboratory for contaminants and potency levels. The Commonwealth's adult-use cannabis market is expected to exceed $1 billion by 2021.

"There are approximately 80 marijuana establishments awaiting licensing, all of which will require testing.  We are scaling up operations considerably to meet the coming adult-use demand for cannabis by year-end.   We expect to be one of just three or four operating labs and are actively hiring for all positions in the lab," said Lori Glauser, COO of EVIO.

About EVIO Inc.
EVIO Inc. is a leading provider of cannabis testing and scientific research for the regulated cannabis industry. The Company's EVIO Labs division operates coast-to-coast providing state-mandated ancillary services to ensure the safety and quality of the nation's cannabis supply. The Company's EVIO Biosciences Division is dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoid system. For more information, visit www.eviolabs.com.

Print